Last reviewed · How we verify
ZED1227
At a glance
| Generic name | ZED1227 |
|---|---|
| Sponsor | Dr. Falk Pharma GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease (PHASE2)
- Different Doses of ZED1227 vs. Placebo in NAFLD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZED1227 CI brief — competitive landscape report
- ZED1227 updates RSS · CI watch RSS
- Dr. Falk Pharma GmbH portfolio CI